actin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-26. Numbers and descriptions here follow the published literature rather than marketing material.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
=== Nonsegmental vitiligo === In NSV, there is usually a degree of symmetry in the location of depigmentation. It tends to affect more skin over time and can occur in patches or over large portions of the body. NSV can occur at any age (while segmental vitiligo usually first appears in teenagers). Classes of nonsegmental vitiligo include the following:
== Further reading == Attenborough, David (1957). Zoo Quest for a Dragon. London: Lutterworth Press. Auffenberg, Walter (1981). The Behavioral Ecology of the Komodo Monitor. Gainesville: University Presses of Florida. ISBN 978-0-8130-0621-5. Burden, W. Douglas (1927). Dragon Lizards of Komodo: An Expedition to the Lost World of the Dutch East Indies. New York, London: G.P. Putnum's Sons. Eberhard, Jo; King, Dennis; Green, Brian; Knight, Frank; Keith Newgrain (1999). Monitors: The Biology of Varanid Lizards. Malabar, Fla: Krieger Publishing Company. ISBN 978-1-57524-112-8. Lutz, Richard L; Lutz, Judy Marie (1997). Komodo: The Living Dragon. Salem, Or: DiMI Press. ISBN 978-0-931625-27-5. Westwood, Brett (28 August 2018). "Natural Histories: Komodo Dragon" (Audio (28 minutes)). BBC Radio. Retrieved 21 April 2023.
Helen Mary Heffernan is a New Zealand microbiologist, specialising in antibiotic resistance. In 2020, she was appointed a Companion of the New Zealand Order of Merit, for services to health. The Institute of Environmental Science and Research awarded Heffernan their Lifetime Achievement Award in 2018.
=== Russia === Russia had plans to ban powdered alcohol in 2016. According to one Russian news site, in 2009, a professor at Saint Petersburg Technological University named Yevgeny Moskalev invented and patented a method of creating alcohol powder. This method could make alcohol powder from any kind of alcoholic beverage.
Sources: en.wikipedia.org
=== Venetia Berens === Venetia Berens (Indy Lewis) is a new grad who joins Pierpoint's FX desk in the second series. She is first seen in series 1 at a Pierpoint recruiting event, pressing Robert and Yasmin on the firm's toxic culture. Ambitious and idealistic, Venetia is determined to prove herself within Pierpoint's cutthroat work environment, provoking resentment from Yasmin over not having to face the same mistreatment she suffered in her first year. In series 2, While scouting new recruits, Venetia grows closer to Robert, to whom she is attracted, but Robert humiliates her when he makes an aggressive pitch to a student while on cocaine, wherein he suggests that Venetia is merely using achievement to seek external validation. Venetia later barges into a client dinner between Robert and Nicole Craig, unaware that they are in a sexual relationship; after Robert leaves the two alone, Nicole sexually assaults Venetia. Venetia confides this to Yasmin, but she dismisses her concerns. Venetia then goes to Kenny, who attempts to report the assault up the chain of command, but to no avail. In series 3, Venetia and Robert have begun dating. Venetia, growing increasingly tired of Pierpoint's abusive work environment, eventually quits the firm. While leaving, she reveals to Rishi that she was the one who anonymously posted to a Reddit page called "Overheard At Pierpoint", which contained many of Rishi's lewd and inappropriate comments on the trading floor.
==== Territorial Control Plan ==== On 19 June 2019, Bukele announced that his government would implement a seven-phase security Territorial Control Plan that sought to disrupt gang finances. The plan began that night at midnight. Phase one, known as "preparation", called for members of the country's security forces — the Armed Forces of El Salvador and the National Civil Police (PNC) — to be stationed in 12 of the country's 262 municipalities at locations where gangs were known to collect renta. The government also implemented a temporary state of emergency in El Salvador's 28 prisons, putting them on lockdown and banning visitors.
=== Democrat Party === Democrat leader Abhisit Vejjajiva stated that the party was prepared to take an opposition role, acknowledging that the Democrats won about 20 seats in the House of Representatives. While accepting that the Democrats fell short in Bangkok, he noted the party's party-list support had significantly increased compared to past elections. Abhisit also pledged to fight corruption and ensure clean governance. When asked about the party's position if invited to a coalition, Abhisit iterated that coalition formation would depend on party conditions, stating that the Democrats would not support any arrangement relating to dark money. He added that the party had not been immediately contacted for coalition talks. The Democrats were certified with 21 seats, four fewer than in 2023, and were left out of the coalition Anutin assembled in March.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.